HomeCompareNSS vs ABBV

NSS vs ABBV: Dividend Comparison 2026

NSS yields 15.23% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $66.5K in total portfolio value· pulled ahead in Year 4
10 years
NSS
NSS
● Live price
15.23%
Share price
$25.44
Annual div
$3.88
5Y div CAGR
-11.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.8K
Annual income
$807.97
Full NSS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NSS vs ABBV

📍 ABBV pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNSSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NSS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NSS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NSS
Annual income on $10K today (after 15% tax)
$1,294.84/yr
After 10yr DRIP, annual income (after tax)
$686.77/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,369.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NSS + ABBV for your $10,000?

NSS: 50%ABBV: 50%
100% ABBV50/50100% NSS
Portfolio after 10yr
$69.1K
Annual income
$12,789.87/yr
Blended yield
18.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NSS
No analyst data
Altman Z
0.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NSS buys
0
ABBV buys
0
No recent congressional trades found for NSS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNSSABBV
Forward yield15.23%3.06%
Annual dividend / share$3.88$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-11.4%40.6%
Portfolio after 10y$35.8K$102.3K
Annual income after 10y$807.97$24,771.77
Total dividends collected$11.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NSS vs ABBV ($10,000, DRIP)

YearNSS PortfolioNSS Income/yrABBV PortfolioABBV Income/yrGap
1$12,050$1,349.68$11,550$430.00+$500.00NSS
2$14,240$1,346.65$13,472$627.96+$768.00NSS
3$16,554$1,317.75$15,906$926.08+$648.00NSS
4← crossover$18,982$1,268.50$19,071$1,382.55$89.00ABBV
5$21,515$1,204.38$23,302$2,095.81$1.8KABBV
6$24,151$1,130.36$29,150$3,237.93$5.0KABBV
7$26,892$1,050.67$37,536$5,121.41$10.6KABBV
8$29,744$968.74$50,079$8,338.38$20.3KABBV
9$32,713$887.20$69,753$14,065.80$37.0KABBV
10$35,811$807.97$102,337$24,771.77$66.5KABBV

NSS vs ABBV: Complete Analysis 2026

NSSStock

NuStar Logistics LP owns and operates crude oil & refined product pipelines and terminals. The company was founded in 1999 and is headquartered in San Antonio, TX.

Full NSS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NSS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NSS vs SCHDNSS vs JEPINSS vs ONSS vs KONSS vs MAINNSS vs JNJNSS vs MRKNSS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.